Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp

<< Previous

Bullboard Posts

Next >>

Post by HarryGlutenon Oct 28, 2021 7:33am

203 Views

Post# 34057618

mdna added new trial sites

$mdna

Updated: 10/27/2021

3 additional sites have been added in Australia. Can go to clinical .gov site Medicenna ability study

https://clinicaltrials.gov/ct2/show/NCT05086692

- Recently received trial site clearance in the u.s. by FDA
- Added more sites in Australia

Things are accelerating. Looking forward to pk/pd safety data in a few weeks -- December 2021

- Heavy tax loss selling right now in the stock as institutions need to sell by Oct. 31 in order to realize losses

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”